Edition:
United Kingdom

PAION AG (PA8G.DE)

PA8G.DE on Xetra

2.48EUR
14 Dec 2017
Change (% chg)

€-0.00 (-0.20%)
Prev Close
€2.48
Open
€2.50
Day's High
€2.51
Day's Low
€2.47
Volume
30,201
Avg. Vol
151,835
52-wk High
€3.53
52-wk Low
€2.15

Chart for

About

PAION AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In... (more)

Overall

Beta: 0.77
Market Cap(Mil.): €162.82
Shares Outstanding(Mil.): 61.12
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-PAION announces clinical development progress with remimazolam

* DGAP-NEWS: PAION ANNOUNCES CLINICAL DEVELOPMENT PROGRESS WITH REMIMAZOLAM BY ITS PARTNER HANA PHARM IN SOUTH KOREA

23 Nov 2017

BRIEF-PAION: FDA considers current human abuse liability program with remimazolam in U.S. as sufficient

* ‍FDA CONSIDERS CURRENT HUMAN ABUSE LIABILITY PROGRAM WITH REMIMAZOLAM IN U.S. AS SUFFICIENT

14 Nov 2017

BRIEF-PAION ‍9-mth net loss at 8.5 mln euros

* DGAP-NEWS: PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2017

08 Nov 2017

BRIEF-Paion: Japan patent office grants dosing patent for remimazolam

* DGAP-NEWS: PAION AG: JAPAN PATENT OFFICE GRANTS DOSING PATENT FOR REMIMAZOLAM IN JAPAN

13 Oct 2017

BRIEF-PAION granted formulation patent for remimazolam in the EU

* DGAP-NEWS: PAION AG: EUROPEAN PATENT OFFICE GRANTS FORMULATION PATENT FOR REMIMAZOLAM IN THE EU

28 Sep 2017

BRIEF-Paion H1 net loss narrows to 5.8 million euros

* ‍NET LOSS FOR FIRST HALF-YEAR 2017 WAS EUR 5.8 MILLION COMPARED TO A NET LOSS OF EUR 13.2 MILLION IN PRIOR-YEAR PERIOD​

09 Aug 2017

BRIEF-Paion: Rr-Pharm starts phase III trial in general anesthesia​

* DGAP-NEWS: PAION ANNOUNCES CLINICAL DEVELOPMENT PROGRESS WITH REMIMAZOLAM BY ITS PARTNER R-PHARM IN RUSSIA

07 Aug 2017

Earnings vs. Estimates